SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition

Peter J. Mullen, Gustavo Garcia, Arunima Purkayastha, Nedas Matulionis, Ernst W. Schmid, Milica Momcilovic, Chandani Sen, Justin Langerman, Arunachalam Ramaiah, David B. Shackelford, Robert Damoiseaux, Samuel W. French, Kathrin Plath, Brigitte N. Gomperts, Vaithilingaraja Arumugaswami and Heather R. Christofk ()
Additional contact information
Peter J. Mullen: University of California, Los Angeles (UCLA)
Gustavo Garcia: UCLA
Arunima Purkayastha: UCLA
Nedas Matulionis: University of California, Los Angeles (UCLA)
Ernst W. Schmid: University of California, Los Angeles (UCLA)
Milica Momcilovic: UCLA
Chandani Sen: UCLA
Justin Langerman: University of California, Los Angeles (UCLA)
Arunachalam Ramaiah: University of California, Irvine
David B. Shackelford: UCLA
Robert Damoiseaux: UCLA
Samuel W. French: UCLA
Kathrin Plath: University of California, Los Angeles (UCLA)
Brigitte N. Gomperts: UCLA
Vaithilingaraja Arumugaswami: UCLA
Heather R. Christofk: University of California, Los Angeles (UCLA)

Nature Communications, 2021, vol. 12, issue 1, 1-10

Abstract: Abstract Viruses hijack host cell metabolism to acquire the building blocks required for replication. Understanding how SARS-CoV-2 alters host cell metabolism may lead to potential treatments for COVID-19. Here we profile metabolic changes conferred by SARS-CoV-2 infection in kidney epithelial cells and lung air-liquid interface (ALI) cultures, and show that SARS-CoV-2 infection increases glucose carbon entry into the TCA cycle via increased pyruvate carboxylase expression. SARS-CoV-2 also reduces oxidative glutamine metabolism while maintaining reductive carboxylation. Consistent with these changes, SARS-CoV-2 infection increases the activity of mTORC1 in cell lines and lung ALI cultures. Lastly, we show evidence of mTORC1 activation in COVID-19 patient lung tissue, and that mTORC1 inhibitors reduce viral replication in kidney epithelial cells and lung ALI cultures. Our results suggest that targeting mTORC1 may be a feasible treatment strategy for COVID-19 patients, although further studies are required to determine the mechanism of inhibition and potential efficacy in patients.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-22166-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22166-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-22166-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().